Redeye initiates coverage of BONESUPPORT, a long-term growth story in bone graft substitutes that we expect to resume its accelerating trajectory next year, particularly in the key US market, as impacts of the corona crisis fades. Nearer-term declines in the share over negative quarterly results would provide attractive entry points for investors.